文献速递糖尿病垂体与肾上腺疾病

未识别肢端肥大症患者中SGLT2抑制剂后快速起病的糖尿病酮症酸中毒

Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

本文报告一例疑似2型糖尿病但未识别肢端肥大症的患者,在二甲双胍、西格列汀和格列齐特基础上加用恩格列净后2天内发生快速起病的严重酮症酸中毒。经蝶窦切除生长激素分泌性大腺瘤后,生长激素和胰岛素样生长因子1浓度恢复正常,糖尿病得到良好控制。作者推测SGLT2抑制剂可能通过其对酮体代谢的固有作用促使活动性肢端肥大症合并糖尿病患者发生酮症酸中毒。

要点

  • 肢端肥大症患者中糖尿病酮症酸中毒罕见,约1%受影响患者可观察到。
  • SGLT2抑制剂可能通过增加胰高血糖素分泌、损害肾脏酮体清除及降低胰岛素后游离脂肪酸升高促发酮症酸中毒。
  • 未识别肢端肥大症合并糖尿病患者使用SGLT2抑制剂后2天内可发生快速起病严重酮症酸中毒。

核心结论

  • 作者推测SGLT2抑制剂可能通过其对酮体代谢的固有作用促使活动性肢端肥大症合并糖尿病患者发生酮症酸中毒。

研究设计与样本

  • 病例报告:一例疑似2型糖尿病但未识别肢端肥大症且伴慢性高血糖的患者,在二甲双胍、西格列汀和格列齐特基础上加用恩格列净。

主要发现

  • 加用恩格列净后2天内发生快速起病的严重酮症酸中毒。
  • 经蝶窦切除生长激素分泌性大腺瘤后,生长激素和胰岛素样生长因子1浓度恢复正常,糖尿病得到良好控制。
  • 肢端肥大症中糖尿病酮症酸中毒罕见,约1%受影响患者可观察到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Diabetic ketoacidosis has been described as a rare complication of acromegaly and may be observed in 1% of affected patients. The well-described direct lipolytic effect of growth hormone results in increased availability of free fatty acids (FFAs) for hepatic ketogenesis and is an important pathogenic event. More recently, ketoacidosis has been identified as an important complication of sodium-glucose-transport-protein 2 inhibitors (SGLT2i). Increased pancreatic glucagon secretion, impaired renal ketone body clearance, and an increase in FFA concentrations secondary to decreased insulin concentrations are likely precipitating factors. CASE DESCRIPTION: We report a case of rapid-onset severe ketoacidosis within 2 days after adding empagliflozin to metformin, sitagliptin, and gliclazide in a presumably type 2 diabetic patient with unrecognized acromegaly and chronic hyperglycemia. Transsphenoidal resection of the growth-hormone secreting macroadenoma restored normal growth-hormone and insulinlike growth factor 1 concentrations and the diabetes was well controlled thereafter. CONCLUSION: We hypothesize that SGLT2i, through their intrinsic effects on ketone body metabolism, may possibly precipitate ketoacidosis in patients with active acromegaly and diabetes mellitus.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Quarella M, Walser D, Brändle M, et al. Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. J Clin Endocrinol Metab. 2017. PMID: 28323955. doi:10.1210/jc.2017-00082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。